Video Summary - Week 02: Lecture 10: Introduction on Lipid-based nanocarriers-II

Main ideas & concepts covered (Week 02: Lecture 10 — Lipid-based nanocarriers II)

The lecture revisits lipid-based nanocarriers and transitions specifically to solid lipid nanoparticles (SLNs).
SLNs are introduced as a lipid-based alternative to:
- liposomes
- emulsions
- polymeric nanoparticles
Key focus areas:
- Definition / basic structure
- Comparison with liposomes
- Composition
- Advantages and disadvantages
- Preparation methods (categorized by mechanism)
- Applications
- One case study: ritonavir-loaded SLNs

Solid Lipid Nanoparticles (SLNs): definition & structure

Definition

SLNs are submicron colloidal carriers.
Size range: ~50 to 100 nm (the slide text notes “50 to … nanometer” with an unclear upper bound in subtitles; another slide mentions a wider range).

Core & dispersion

Comprised mainly of solid lipids:
- solid lipid core dispersed in water or a surfactant/emulsifier solution.

Why they are solid

The selected lipid should remain solid at both room temperature and body temperature.

Difference vs liposomes (core concept)

Liposomes

Based on bilayer lipid structures.
Often limited by:
- low drug loading
- drug leakage
- degradation issues such as oxidation and rancidity

SLNs

Use solid lipids as the major component (instead of fluid phospholipid bilayers).
Offer more stability due to a:
- rigid solid core
- emulsifier/surfactant layer surrounding it

Composition of SLNs

1) Solid lipids (main component)

Lipids determine:

stability
release behavior
encapsulation
drug loading

Minimum selection requirement:

Lipid melting point > 40°C

Examples of solid lipids:

Fatty acids
Triglycerides / glycerides / glycerols
Waxes
Cationic lipids (used to overcome negative charge by complexing with negatively charged molecules)

2) Surfactants / emulsifiers (outer stabilizing layer)

Surfactants:

reduce interfacial tension between oil (lipid) and water phases
help convert melted solid lipid into dispersion in the aqueous phase
support stabilization after cooling, enabling nanoparticle formation in the solid state

Surfactant classification by electrical charge

Ionic (charged) surfactants
- Anionic: e.g., sodium dodecyl sulfate → negative charge
- Cationic: ammonium-group emulsifiers → positive charge (supports complexation)
Nonionic surfactants (no charge)
- examples: Pluronic F68, Tween 20, Tween 80
Zwitterionic / amphoteric
- examples: amphoteric agents of the phosphatidylcholine type
Co-surfactants (sometimes used, e.g., with microemulsions)
- examples listed (some text unclear in the notes): ethanol, low-molecular-weight PEG/PPG, sorbitan monostearate (spelling varies), and “beta…” (unclear)

Advantages of SLNs (vs other formulations)

Higher storage stability
- rigid solid core reduces instability relative to liposomes
Scalability
- preparation can use scale-up-compatible techniques, notably:
  - high-pressure homogenization (lab → pilot → industrial)
- continuous processes also mentioned
Lower toxicity vs polymeric nanoparticles (as stated)
Improved bioavailability
- especially for water-insoluble / poorly soluble drugs
- lipid + surfactant effects enhance solubility → improved absorption
Potential for targeting and improved penetration
- penetration enhancement through skin for topical/cosmetic use (described)
- possible active targeting via surface modification (e.g., ligands/antibodies)
Protection of payload
- protects against harsh environments such as:
  - acidic conditions
  - enzymatic degradation
Controlled release / controlled degradation
- release/degradation can be tuned by formulation design

Disadvantages / limitations of SLNs

Polymorphic transitions during storage
- lipid crystals may change solid forms → impacts performance
Drug expulsion / leakage during storage
- drug may migrate out over time
Particle growth and aggregation
- nanoparticles may grow (e.g., toward micron scale) due to particle attraction
Microbial growth risk
- can be controlled using preservatives (as stated)
Active targeting is difficult
- harder to modify lipid surfaces than polymer nanoparticles
High manufacturing cost
- requires specialized nano-technology equipment, processing steps, and purification
- material costs can be high for parenteral use
Regulatory challenges
- strict need for CMC documentation per material for approval

Methods of preparation of SLNs (detailed bullet list)

The lecture groups SLN preparation methods into three mechanism-based categories.

A) High-energy methods

Purpose
- mechanical/high energy reduction of size from micron → nano
- increased surface area → improved solubility/bioavailability

High-pressure homogenization
- lipid dispersion passed through a high-pressure system
- pressure range: ~500 to 5,000 bar
- can be run in hot or cold conditions depending on material properties
Ultrasonication
- cavitation mechanism:
  - bubble formation → bubble collapse breaks larger particles into smaller ones
High-speed homogenization
- primarily via shear force
- noted as having less size reduction capacity than high-pressure homogenization

Special processing note

Supercritical fluid (e.g., CO₂) is mentioned as a method that can reduce particle size and enable formation of lipid/polymer/inorganic nanoparticles.

B) Low-energy methods

Purpose
- minimum energy required for size reduction
- simpler processing with less energy consumption

Simple mixing / stirring (emulsification-type)
- mixing forms nanoscale particles with minimal energy
Microemulsion method
- does not require high energy (as described)
Nanoemulsion methods
- generally require more energy than microemulsions:
  - “nano emulsion required high pressure / ultrasonication / high speed homogenization”
Single emulsification / double emulsification
- included under low-energy category in the subtitles

C) Methods based on organic solvents

Purpose
- dissolve lipid in an organic solvent, then emulsify into an aqueous phase

Process outline

dissolve lipid in solvent
emulsify into water (aqueous phase)
remove solvent after formation via:
- solvent evaporation
- solvent diffusion

Applications of SLNs (as described)

Oral drug delivery
- enhance bioavailability of water-insoluble drugs
Parenteral delivery
- controlled release for:
  - intravenous systems
  - intramuscular systems
- described as supporting “long-acting injectables”
- can be used after sterilization
Topical and cosmetic applications
- enhanced skin penetration due to lipid nature
Targeted cancer therapy (active targeting)
- surface labeling with:
  - monoclonal antibodies
  - other ligands to reach cancer sites
Immunotherapy / antigen delivery
- encapsulate antigens to enhance immune response vs plain antigens
Gene delivery
- complexing with cationic lipids in SLN formulations
Broad payload capability
- encapsulate small drugs and also biological molecules, such as:
  - proteins
  - peptides
  - monoclonal antibodies
- mentions cosmetic products as well

Case study: ritonavir-loaded SLNs for oral delivery

Study goal

Improve oral drug delivery and bioavailability of ritonavir.

Problem

Ritonavir has low aqueous solubility → low absorption → low bioavailability.

Formulation approach

SLNs prepared using:
- hot homogenization
- ultrasonication
Optimized results:
- particle size: ~265 nm
- encapsulation efficiency: ~86%
- release: ~94%

In vivo results (rats)

Enhanced oral bioavailability vs market/conventional formulation.
Reported enhancement: ~4.34× (SLN vs conventional market formulation).

Conclusion of the lecture

Learned what SLNs are
Reviewed:
- composition (solid lipids + surfactants)
- types of solid lipids
- advantages and disadvantages
- preparation methods
- applications
Ended with the ritonavir SLN case study

Speakers / sources featured

Dr. Satish Dawanapali (Assistant Professor, Department of Pharmaceutical Sciences and Technology, Mumbai) — primary lecturer
Case study source (unspecified) — referenced study on ritonavir-loaded SLNs (no authors/journal named in the subtitles)

Week 02: Lecture 10: Introduction on Lipid-based nanocarriers-II

Key takeaways